Antibody-drug conjugates (ADCs) may have fallen behind immunotherapy in the oncology-hype department, but plenty of companies are pressing forward with their ADC drugs. Last week, there was an entire conference – the 2015 World ADC Summit – held in San Diego dedicated to the discovery, development and manufacturing of ADCs.